{
    "clinical_study": {
        "@rank": "110960", 
        "acronym": "BESTFIT", 
        "arm_group": [
            {
                "arm_group_label": "TNX-102 SL 2.8 mg Tablets", 
                "arm_group_type": "Experimental", 
                "description": "1 x TNX-102 SL 2.8mg Tablet taken sublingually each day at bedtime for 12 weeks."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "1 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "TNX-102 capsules [formerly known as very low dose (VLD) cyclobenzaprine] at bedtime has\n      shown promise as a treatment of fibromyalgia, but the drug required new formulation\n      technology for bedtime use. The present trial is designed to assess the safety and efficacy\n      of TNX-102 SL 2.8 mg tablets, taken daily at bedtime over 12 weeks to treat fibromyalgia."
        }, 
        "brief_title": "BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Primary Fibromyalgia", 
        "condition_browse": {
            "mesh_term": [
                "Fibromyalgia", 
                "Myofascial Pain Syndromes"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of Primary Fibromyalgia (ACR criteria)\n\n          -  Male or female 18-65 years old\n\n          -  For patients with major depressive disorders only: clinically stable, no suicidal\n             risk and stable anti-depressent therapy\n\n          -  Willing and able to withdraw specific therapies (ask PI)\n\n          -  Medically acceptable form of contraception (female only)\n\n          -  Signed informed consent\n\n        Exclusion Criteria:\n\n          -  Arthritis, lupus and other systemic auto-immune diseases\n\n          -  Regional or persistent pain that could interfere with assessment of fibromyalgia pain\n\n          -  Bipolar and psychotic disorders\n\n          -  Increase risk of suicide\n\n          -  Significant clinical (cardiac, systemic infection, systemic corticosteroid\n             requirement, drug/alcohol abuse) or laboratory abnormalities.\n\n          -  Unability to wash-out specific medications (ask PI)\n\n          -  Known hypersensitivity to cyclobenzaprine\n\n          -  Others: seizure disorders, sleep apnea, CPAP use, BMI>40"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01903265", 
            "org_study_id": "TNX-CY-F202"
        }, 
        "intervention": [
            {
                "arm_group_label": "TNX-102 SL 2.8 mg Tablets", 
                "description": "Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.", 
                "intervention_name": "TNX-102 SL 2.8mg Tablets", 
                "intervention_type": "Drug", 
                "other_name": "Low dose cyclobenzaprine sublingual tablets"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo sublingual tablets"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Cyclobenzaprine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "pain", 
            "sleep"
        ], 
        "lastchanged_date": "May 15, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80239"
                    }, 
                    "name": "Radiant Research, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brooksville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34601"
                    }, 
                    "name": "16176 Cortez Boulevard"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32806"
                    }, 
                    "name": "100 West Gore Street"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frederick", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21702"
                    }, 
                    "name": "71 Thomas Johnson Drive"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "North Dartmouth", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02747"
                    }, 
                    "name": "370 Faunce Corner Road"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Worcester", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "01605"
                    }, 
                    "name": "Clinical Pharmacology Study Group"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jackson", 
                        "country": "United States", 
                        "state": "Mississippi", 
                        "zip": "39202"
                    }, 
                    "name": "CRC of Jackson, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45219"
                    }, 
                    "name": "University of Cincinnati College of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43212"
                    }, 
                    "name": "1275 Olentangy River Road"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Middleburg Heights", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44130"
                    }, 
                    "name": "18660 Bagley Road"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mechanicsburg", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "17055"
                    }, 
                    "name": "1001 South Market Street"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greer", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29650"
                    }, 
                    "name": "322 Memorial Drive"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98122"
                    }, 
                    "name": "601 Broadway"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2b, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Tablets Taken at Bedtime in Patients With Fibromyalgia", 
        "overall_official": [
            {
                "affiliation": "Premier Research", 
                "last_name": "Mark R. Schmal", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Ann Harbor, MI", 
                "last_name": "Daniel J. Clauw, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the efficacy of TNX-102 (low-dose cyclobenzaprine) sublingual (SL) tablets taken at bedtime over 12 weeks of treatment using an 11-point (0-10) numerical rating scale (NRS) to assess average daily pain over 24 hours.", 
            "measure": "Average perceived pain", 
            "safety_issue": "No", 
            "time_frame": "Weeks 12 mean change of perceived average pain intensity from baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01903265"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Patient's Global Impression of Change", 
                "safety_issue": "No", 
                "time_frame": "Weeks 2, 4, 8 and 12 or early termination"
            }, 
            {
                "measure": "Fibromyalgia Impact Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Baseline and weeks 2, 4, 8 and 12"
            }, 
            {
                "measure": "Patient pain improvement response rate", 
                "safety_issue": "No", 
                "time_frame": "Weekly"
            }, 
            {
                "measure": "SF-36 Physical Component score", 
                "safety_issue": "No", 
                "time_frame": "Baseline and weeks 4, 8 and 12"
            }, 
            {
                "description": "Every adverse events occurring during the study period will be reported.", 
                "measure": "Safety of TNX-102 SL Tablets", 
                "safety_issue": "Yes", 
                "time_frame": "Continuously throughout the treatment period (total duration: about 3 months)"
            }
        ], 
        "source": "Tonix Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tonix Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}